Societies

Endocrine-Related Cancer is owned by the Society for Endocrinology. The Society for Endocrinology is a UK-based membership organisation representing a global community of scientists, clinicians and nurses who work with hormones. Members of the Society for Endocrinology enjoy free online access to the current content of Endocrine-Related Cancer, via the society members' area, and reduced rates on print subscriptions.

Endocrine-Related Cancer is an official journal of the Japanese Hormone and Cancer Society (JHCS). JHCS is a non-profit organisation of health care workers and scientists, whose goal is to investigate the diagnosis and treatment of hormone-dependent cancers in patients. It performs a wide range of awareness-raising activities, including education and training, and aims to contribute to the development of medicine.

Endocrine-Related Cancer is an official journal of the Endocrine Society of Australia (ESA). Founded in 1958, ESA is a national non-profit organisation of scientists and clinicians whose purpose is to educate about, engage in and promote clinical practice and research in endocrinology in the region and world-wide. Its primary activities include education, research and fostering communication between clinicians, scientists, the public and policy makers.

Endocrine-Related Cancer is an official journal of The North American Neuroendocrine Tumor Society (NANETS). NANETs is a society of over 400 multidisciplinary medical professionals committed to the support of the medical community in treating neuroendocrine tumor (NET) patients, as well as furthering NET science and education in North America. NANETS offers comprehensive, accredited medical education programs on NET disease that are developed by leading NET experts and designed exclusively for medical professionals. The NANETS community is actively engaged in research, consensus guidelines, education and mentoring of young professionals.

Endocrine-Related Cancer is an official journal of the Neuroendocrine Tumor Research Foundation (NETRF). NETRF is the largest global funder of neuroendocrine cancer research. Founded in 2005, NETRF has invested $40 million in research to develop new treatments and cures.  NETRF has expanded the neuroendocrine cancer research community through its funding and its annual Research Symposium.  NETRF also provides educational resources for patients so they can understand treatment options, clinical trials, and strategies to thrive.